Drug intelligence / Profile preview

HEC-016

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Cell Therapies
Administration: Intravenous

Overview

HEC-016 is a **chimeric antigen receptor T cell (CAR-T) therapy** that specifically targets **Claudin 18.2 (CLDN18.2)**, a protein highly expressed in certain cancers. It is currently in **early clinical development** for advanced **gastroesophageal junction adenocarcinoma** and **pancreatic cancer**.

Beyond the preview

Go deeper on HEC-016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC-016.

Explore the full profile